紫杉醇联合顺铂同步放疗盆腔淋巴结阳性Ⅲ期宫颈癌临床效果分析

Clinical e ffect analysis of paclitaxel combined with cisplatin in the treatment of pelvic lymph node-positive stage Ⅲ cervical cancer

目的:研析紫杉醇复合顺铂同步放疗盆腔淋巴结阳性Ⅲ期宫颈癌的疗效。方法:择取2017年6月-2018年10月到我院诊治的74例Ⅲ期宫颈癌患者资料,随机分成两组,37例采取顺铂单药同步放疗(对照组),37例采取紫杉醇复合顺铂同步放疗(研究组),比对两组的近期疗效与不良反应。结果:研究组医治有效率97.29%高于对照组72.97%,比较差异显著具有统计学意义(P<0.05),且两组毒副反应率比较无明显差异(P>0.05)。结论:紫杉醇复合顺铂同步放疗盆腔淋巴结阳性Ⅲ期宫颈癌的近期疗效较佳,不良反应均可耐受。

Objective:To study the efficacy of paclitaxel combined with cisplatin in the treatment of pelvic lymph node-positive stage Ⅲ cervical cancer.Methods:74 patients with stage Ⅲ cervical cancer who were admitted to our hospital from June 2017 to May 2018 were randomly divided into two groups.37 patients received cisplatin single-agent concurrent radiotherapy(the control group),and 37 patients received Paclitaxel combined with cisplatin synchronous radiotherapy(the study group),the short-term efficacy and side effects of the two groups were compared.Results:The effective rate of treatment in the study group was 97.29%,which was higher than that in the control group(72.97%).The difference was statistically signi ficant(P<0.05),and there was no significant difference between the two groups in side effects(P>0.05).Conclusion:The short-term effect of paclitaxel combined with cisplatin is better in the treatment of pelvic lymph node-positive stage III cervical cancer,and the toxicity can be tolerated.